Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures - Top-Institutions - MDSpire

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • By

  • Mohammed Nabil Quraishi

  • Jonathan Cheesbrough

  • Peter Rimmer

  • Benjamin H Mullish

  • Naveen Sharma

  • Elena Efstathiou

  • Animesh Acharjee

  • Georgios Gkoutus

  • Arzoo Patel

  • Julian R Marchesi

  • Stephane Camuzeaux

  • Katie Chappell

  • Maria A Valdivia-Garcia

  • James Ferguson

  • Matthew J Brookes

  • Martine Walmsley

  • Amanda E Rossiter

  • Willem van Schaik

  • Ross S McInnes

  • Rachel Cooney

  • Michael Trauner

  • Andrew D Beggs

  • Tariq H Iqbal

  • Palak J Trivedi

  • December 14, 2024

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Hepatology
    • Inflammatory Bowel Disease
    • Microbiome Research

  • #2

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Gastroenterology
    • Hepatology
    • Inflammatory Bowel Disease

  • #3

    Mount Sinai Health System
    Mount Sinai Health System

    New York, NY

    Key Differentiators

    • Gastroenterology
    • Hepatology
    • Microbiome Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Gastroenterology
    • Hepatology
    • Inflammatory Bowel Disease
    • Microbiome Science

  • #5

    University of Cambridge
    University of Cambridge

    Cambridge, UK

    Key Differentiators

    • Gastroenterology
    • Hepatology
    • Microbiome Research

Original Source(s)

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • by Mohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, Benjamin H Mullish, Naveen Sharma, Elena Efstathiou, Animesh Acharjee, Georgios Gkoutus, Arzoo Patel, Julian R Marchesi, Stephane Camuzeaux, Katie Chappell, Maria A Valdivia-Garcia, James Ferguson, Matthew J Brookes, Martine Walmsley, Amanda E Rossiter, Willem van Schaik, Ross S McInnes, Rachel Cooney, Michael Trauner, Andrew D Beggs, Tariq H Iqbal, Palak J Trivedi

  • December 14, 2024

Related Content

Grape seed proanthocyanidins supplementation attenuates diquat-induced intestinal barrier damage in weaned pigs

The Oral Microbiome's Role: Linking Periodontal Dysbiosis to Systemic Health Issues

Integrase inhibitor–based antiretroviral therapy drives gut microbiota remodeling and immune recovery in HIV infection